A Safety and Effectiveness Study of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Pain Associated With Ankle Sprains.
A Randomized, Double-Blind, Parallel-Group Study Comparing the Safety and Effectiveness of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Ankle Sprains.
Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide
Listed as NCT00261560, this PHASE4 trial focuses on Pain and Sprains and Strains and remains completed. Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide, it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Consumer and Personal Products Worldwide
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.